FDA Approves Baxfendy for the Treatment of Uncontrolled Hypertension

For the roughly 50% of Americans with hypertension who are already taking multiple blood pressure medications and still cannot get their numbers under control, options have been frustratingly limited — until now. The U.S. Food and Drug Administration (FDA) has approved Baxfendy (baxdrostat), a first-in-class treatment that works in an entirely new way to lower blood pressure, marking the most significant therapeutic advancement in hypertension care in nearly two decades.

“We have been waiting for an innovative medication like Baxfendy for hypertension for many years,” said the BaxHTN study’s lead investigator, Bryan Williams, M.D., chair of medicine at University College London. “Its novel way of lowering blood pressure has the potential to transform clinical practice by targeting a root cause of persistently uncontrolled hypertension.”

Hypertension, or high blood pressure, affects an estimated 1.4 billion people worldwide and remains the single most prevalent modifiable risk factor for cardiovascular disease globally. In the United States alone, approximately 23 million patients remain uncontrolled despite taking two or more antihypertensive medications. Over time, persistently elevated blood pressure silently damages blood vessels and vital organs, significantly raising the risk of heart attack, stroke, heart failure, kidney disease and dementia.

How Baxfendy Works

What makes Baxfendy different from existing blood pressure treatments is its mechanism of action. It is a highly selective aldosterone synthase inhibitor, meaning it works by specifically blocking the production of aldosterone — a hormone that raises blood pressure by causing the body to retain sodium and water. Elevated aldosterone levels are strongly associated with treatment-resistant hypertension and the progression of both heart failure and kidney disease. By targeting aldosterone production at its source rather than simply managing its downstream effects, Baxfendy addresses a root cause of persistently uncontrolled blood pressure.

What the Clinical Trial Showed

The FDA approval was based on results from the BaxHTN Phase 3 trial, published in the New England Journal of Medicine. The trial enrolled 796 patients with uncontrolled or resistant hypertension who were already on standard-of-care medications.

At 12 weeks, patients taking Baxfendy 2 milligrams saw their systolic blood pressure drop by an average of 15.7 mm Hg from baseline, with a placebo-adjusted reduction of 9.8 mm Hg — a clinically meaningful result. The 1-milligram dose produced a placebo-adjusted reduction of 8.7 mm Hg. Results were consistent across both uncontrolled and treatment-resistant patient groups, and Baxfendy was generally well tolerated with no unanticipated safety findings.

To put those numbers in context, epidemiological data suggest that a 10 mm Hg decrease in systolic blood pressure is associated with approximately a 20% lower risk of serious cardiovascular events — making a nearly double-digit placebo-adjusted reduction genuinely significant for patients and clinicians alike.

What This Means for Patients

Baxfendy is approved for use in combination with other antihypertensive medications in adults whose blood pressure is not adequately controlled. It is taken orally once daily, making it straightforward to incorporate into an existing treatment regimen. For patients who have cycled through multiple medications without achieving target blood pressure levels, this approval represents a meaningful new pathway — one that targets the hormonal underpinnings of their condition rather than simply adding another agent with a familiar mechanism.